Page 33 - 2021_07-Haematologica-web

Conditioning intensity in allogeneic HSCT
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275-1291.
44. Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015;29(2):312- 320.
45. Zhou Y, Othus M, Araki D, et al. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multipara- meter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30(7): 1456-1464.
46.Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogene- ic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38(12):1273- 1283.
47. Gilleece MH, Labopin M, Yakoub-Agha I, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplanta- tion for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018;93(9):1142-1152.
48. Bachanova V, Marks DI, Zhang M-J, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplanta- tion: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014;28(3):658-665.
49. Morsink LM, Sandmaier BM, Othus M, et al. Conditioning intensity, pre-transplant flow cytometric measurable residual dis- ease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Cancers. 2020;12(9):2339.
50. Festuccia M, Deeg HJ, Gooley TA, et al. Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syn- drome and acute myelogenous leukemia evolving from myelodysplastic syndrome. Biol Blood Marrow Transplant 2016;22(7): 1227-1233.
51. Milano F, Gooley T, Wood B, et al. Cord- blood transplantation in patients with mini- mal residual disease. N Engl J Med. 2016;375(10):944-953.
52. Chang Y-J, Wang Y, Liu Y-R, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicat- ing pre-transplantation minimal residual dis- ease of AML patients as determined by mul- tiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10(1):134.
53. Armand P, Gibson CJ, Cutler C, et al. A dis- ease risk index for patients undergoing allo- geneic stem cell transplantation. Blood. 2012;120(4):905-913.
54.Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplan- tation. Blood. 2014;123(23):3664-3671.
55. Solh MM, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A. The dilemma of conditioning intensity: when does myeloab- lative conditioning improve outcomes for allogeneic hematopoietic cell transplanta- tion. Biol Blood Marrow Transplant. 2019;25 (3):606-612.
56. Bejanyan N, Zhang M, Bo-Subait K. Myeloablative conditioning for allogeneic transplantation results in superior disease- free survival for acute myeloid leukemia and myelodysplastic syndromes with low/inter- mediate, but not high disease risk Index: a CIBMTR study. Transplant Cell Ther. 2021;27(1):68.e1-68.e9.
57. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47(6):749-756.
58. Gratwohl A, Duarte R, Snowden JA, et al.
Pre-transplantation risks and transplant- techniques in haematopoietic stem cell transplantation for acute leukaemia. EClinicalMedicine. 2019;15:33-41.
59. Gagelmann N, Ditschkowski M, Bogdanov R, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133(20):2233-2242.
60. Gagelmann N, Eikema D-J, Stelljes M, et al. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica. 2019;104(5):929-936.
61. Shaffer BC, Ahn KW, Hu Z-H, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syn- drome. J Clin Oncol. 2016;34(16):1864-1871.
62. Versluis J, Cornelissen JJ. Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR. Semin Hematol. 2019;56(2):164-170.
63. Konuma T, Kondo T, Mizuno S. Conditioning intensity for allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with poor-prog- nosis cytogenetics in first complete remis- sion. Biol Blood Marrow Transplant. 2020;26(3):463-471.
64. Versluis J, Labopin M, Ruggeri A, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017;1 (7):477-485.
65. Passweg JR, Labopin M, Cornelissen J, et al. Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2015;50 (8):1063-1068.
66.Myllymäki M, Redd R, Reilly CR, et al. Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 2020;136 (26):3070-3081.
67.Akahoshi Y, Nishiwaki S, Arai Y, et al. Reduced-intensity conditioning is a reason- able alternative for Philadelphia chromo- some-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. Bone Marrow Transplant. 2020;55(7):1317-1325.
68.Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
69. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002- 2007.
70. Fein JA, Shimoni A, Labopin M, et al. The impact of individual comorbidities on non-
relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia. 2018;32(8):1787-1794.
71. Gilleece MH, Labopin M, Savani BN, et al. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second com- plete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia. 2020;34(1):87-99.
72. Sengsayadeth S, Gatwood KS, Boumendil A, et al. Conditioning intensity in secondary AML with prior myelodysplastic syn- drome/myeloproliferative disorders: an EBMT ALWP study. Blood Adv. 2018;2(16): 2127-2135.
73. Saraceni F, Labopin M, Forcade E, et al. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Med. 2021;10(1):23-33.
74. Sorror ML, Estey E. Allogeneic hematopoiet- ic cell transplantation for acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program. 2014;2014:21- 33.
75.Castagna L, Fürst S, Marchetti N, et al. Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-inten- sity conditioning regimen and alloSCT. Bone Marrow Transplant. 2011;46(7): 1000-1005.
76. Martino R, Caballero MD, Canals C, et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;28(4):341- 347.
77. Ustun C, Kim S, Chen M, et al. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Adv. 2019;3(17): 2525-2536.
78. Shouval R, Kouniavski E, Fein J, et al. Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2019;103(4):402-409.
79. Shimoni A, Labopin M, Savani B, et al. Long-term survival and late events after allo- geneic stem cell transplantation from HLA- matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol. 2016;9 (1):118.
80. Storb R, Gyurkocza B, Storer BE, et al. Graft- versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12): 1530-1538.
81. Gagelmann N, Bacigalupo A, Rambaldi A, et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide ther- apy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis. JAMA Oncol. 2019;5(12):1739-1748.
82.Brissot E, Labopin M, Ehninger G, et al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refrac- tory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. Haematologica. 2019;104(3):524-532.
83. Ciurea SO, Zhang M-J, Bacigalupo AA, et al.
haematologica | 2021; 106(7)
1803